Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for prostate cancer.

R Postma1, F H Schröder

  • 1Department of Urology, Josephine Nefkens Institute, Erasmus MC, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands. r.postma@erasmusmc.nl

European Journal of Cancer (Oxford, England : 1990)
|April 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-hospital care after return of spontaneous circulation: Are we achieving our targets?

Resuscitation plus·2024
Same author

What is the potential benefit of pre-hospital extracorporeal cardiopulmonary resuscitation for patients with an out-of-hospital cardiac arrest? A predictive modelling study.

Resuscitation·2023
Same author

Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

Journal of the National Cancer Institute·2014
Same author

Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors.

British journal of cancer·2013
Same author

Theory and experiment in concert: the [MeOC:O]+ ion and its isomers.

Journal of the American Chemical Society·2012
Same author

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.

World journal of urology·2011
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

Prostate cancer screening is currently not justified due to a lack of clinical trial data and the risk of over-treatment. Further evidence is needed before widespread screening can be recommended.

Area of Science:

  • Oncology
  • Public Health
  • Diagnostic Medicine

Background:

  • Prostate cancer is a leading cancer in Western countries.
  • Current screening methods like the prostate-specific antigen (PSA) test have limitations.
  • The justification for prostate cancer screening remains uncertain due to insufficient clinical trial evidence.

Purpose of the Study:

  • To evaluate the current evidence regarding prostate cancer screening.
  • To discuss the benefits and risks associated with prostate cancer screening.
  • To determine the conditions under which prostate cancer screening may be justified.

Main Methods:

  • Review of existing epidemiological data.
  • Analysis of the efficacy and limitations of prostate cancer screening tests.

Related Experiment Videos

  • Discussion of the implications of overdiagnosis and over-treatment.

    • Main Results:

    • Screening can lead to earlier detection of localized and well-differentiated tumors.
    • However, screening tests may fail to detect cancers leading to mortality.
    • Overdiagnosis and subsequent over-treatment pose significant risks.

    Conclusions:

    • Prostate cancer screening is not definitively justified without robust clinical trial data.
    • The potential for over-treatment necessitates caution.
    • Screening should be confined to clinical trials until further evidence emerges.